CN112424606B9 - 用于检测创伤性脑损伤的组合物和方法 - Google Patents

用于检测创伤性脑损伤的组合物和方法 Download PDF

Info

Publication number
CN112424606B9
CN112424606B9 CN201980044404.1A CN201980044404A CN112424606B9 CN 112424606 B9 CN112424606 B9 CN 112424606B9 CN 201980044404 A CN201980044404 A CN 201980044404A CN 112424606 B9 CN112424606 B9 CN 112424606B9
Authority
CN
China
Prior art keywords
certain embodiments
patient
compound
use according
probe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980044404.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN112424606A (zh
CN112424606B (zh
Inventor
S·萨拉夫
L·M·伦道夫
S·拉苏尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amidas
Original Assignee
Amidas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amidas filed Critical Amidas
Priority to CN202411990187.4A priority Critical patent/CN119985995A/zh
Publication of CN112424606A publication Critical patent/CN112424606A/zh
Application granted granted Critical
Publication of CN112424606B publication Critical patent/CN112424606B/zh
Publication of CN112424606B9 publication Critical patent/CN112424606B9/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/4064—Evaluating the brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Eye Examination Apparatus (AREA)
CN201980044404.1A 2018-05-31 2019-05-31 用于检测创伤性脑损伤的组合物和方法 Active CN112424606B9 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411990187.4A CN119985995A (zh) 2018-05-31 2019-05-31 用于检测创伤性脑损伤的组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862678900P 2018-05-31 2018-05-31
US62/678,900 2018-05-31
US201862733025P 2018-09-18 2018-09-18
US62/733,025 2018-09-18
PCT/US2019/034977 WO2019232422A1 (en) 2018-05-31 2019-05-31 Compositions and methods for detection of traumatic brain injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411990187.4A Division CN119985995A (zh) 2018-05-31 2019-05-31 用于检测创伤性脑损伤的组合物和方法

Publications (3)

Publication Number Publication Date
CN112424606A CN112424606A (zh) 2021-02-26
CN112424606B CN112424606B (zh) 2025-01-14
CN112424606B9 true CN112424606B9 (zh) 2025-03-07

Family

ID=68697319

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980044404.1A Active CN112424606B9 (zh) 2018-05-31 2019-05-31 用于检测创伤性脑损伤的组合物和方法
CN202411990187.4A Pending CN119985995A (zh) 2018-05-31 2019-05-31 用于检测创伤性脑损伤的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411990187.4A Pending CN119985995A (zh) 2018-05-31 2019-05-31 用于检测创伤性脑损伤的组合物和方法

Country Status (8)

Country Link
US (1) US12478693B2 (https=)
EP (1) EP3803416A4 (https=)
JP (3) JP7381500B2 (https=)
CN (2) CN112424606B9 (https=)
AU (1) AU2019279001B2 (https=)
CA (1) CA3100700A1 (https=)
MA (1) MA52796A (https=)
WO (1) WO2019232422A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019372432B2 (en) * 2018-11-02 2025-05-29 Amydis, Inc. Phosphate compounds for detecting neurological disorders
AU2020348382A1 (en) * 2019-09-18 2022-04-28 Amydis, Inc. Methods of detecting neurological disorders via binding to phosphorylated tau protein
JP2024525693A (ja) * 2021-07-15 2024-07-12 アミディス， インコーポレイテッド 神経変性障害の診断のためにアミロイドおよびアミロイド様タンパク質を検出するためのフルオロフォアとしてのｎ－ヘテロシクリル置換２－シアノ－３－（ナフタレン－２－イル）アクリルアミド誘導体
WO2024155678A1 (en) * 2023-01-18 2024-07-25 Amydis, Inc. Amyloid targeting agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143185A1 (en) * 2014-03-19 2015-09-24 Amydis Diagnostics Amyloid targeting agents and methods of using the same
WO2015188142A1 (en) * 2014-06-05 2015-12-10 Cedars-Sinai Medical Center Diagnosis and monitoring of traumatic brain injury by imaging retinal abnormalities
CN113271944A (zh) * 2018-11-02 2021-08-17 阿米达斯公司 用于对神经疾病进行检测的磷酸盐化合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043013A (en) 1987-12-30 1991-08-27 Milliken Research Corporation Washable ink compositions
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US6541454B1 (en) 1995-04-04 2003-04-01 Yissum Research Development Company Of The Hebrew University Jerusalem Phosphonates, biphosphonates and pharmaceutical compositions containing them
US6048662A (en) 1998-12-15 2000-04-11 Bruhnke; John D. Antireflective coatings comprising poly(oxyalkylene) colorants
DE10047237A1 (de) 2000-09-23 2002-04-11 Physoptics Opto Electronic Gmb System zur Aufnahme des Netzhautreflexbildes
JPWO2003020690A1 (ja) 2001-08-29 2004-12-16 協和醗酵工業株式会社 アリールスルファマート誘導体
JP2007504283A (ja) 2003-05-20 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア β−アミロイド斑に作用物質を結合させる方法
CN101103018A (zh) * 2004-11-16 2008-01-09 神经化学（国际）有限公司 治疗cns和淀粉样蛋白-相关疾病的化合物
ATE525664T1 (de) 2004-11-22 2011-10-15 Abbott Medical Optics Inc Copolymerisierbare methin- und anthrachinon- verbindungen und artikel damit
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
JP2008013446A (ja) 2006-07-03 2008-01-24 Neugen Pharma:Kk 酸化ストレスによる細胞変性を分子背景とする難治性疾患の治療または予防剤
EP2046322A4 (en) 2006-08-02 2010-10-06 Univ Temple ARYL-VINYL-SULFIDE, -SULFONE, -SULFOXIDE AND -SULFONAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC APPLICATIONS THEREOF
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP3231804B1 (en) 2008-03-21 2021-03-03 The General Hospital Corporation Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
JP5771525B2 (ja) 2008-09-18 2015-09-02 セダーズ−シナイ メディカル センター アルツハイマー病を検出するための光学的方法
US20120282169A1 (en) 2009-11-06 2012-11-08 Adlyfe, Inc. Detection and treatment of traumatic brain injury
SI2509940T1 (sl) 2009-12-10 2015-09-30 The Regents Of The University Of California Sredstva za vezavo amiloida
CN102115429B (zh) 2010-01-06 2013-02-27 中国科学院上海药物研究所 (e)-1-(3,5-二甲氧基苯基)-2-(3,5-二羟基-4-甲氧基苯基)乙烯及其制备方法和用途
KR101194337B1 (ko) 2010-07-14 2012-10-24 웅진코웨이주식회사 레티노이드 유도체 및 그를 포함하는 화장료 조성물
CA2807683C (en) 2010-08-16 2020-02-18 Cognoptix, Inc. System and method for detecting amyloid proteins
CA2814198A1 (en) 2010-10-25 2012-05-10 Steven Verdooner Apparatus and method for detecting amyloid in a retina in a diagnosis, advancement, and prognosing of alzheimer's disease, traumatic brain injury, macular degeneration and a plurality of neurodegenerative dissorders, and ocular diseases
RU2627694C2 (ru) 2010-10-29 2017-08-10 Клино Лтд. Производные хинолина, визуализирующий белок тау
US9588129B2 (en) 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
EP3068283A1 (en) 2013-11-12 2016-09-21 Cognoptix, Inc. Method for measuring fluorescence in ocular tissue
US9605315B2 (en) * 2014-03-26 2017-03-28 The University Of Montana Detection of traumatic brain injury
WO2016040891A2 (en) 2014-09-12 2016-03-17 Amydis Diagnostics In vitro compositions comprising human sample and amyloid targeting agent
WO2016055148A2 (en) 2014-10-06 2016-04-14 Université De Genève Markers and their use in brain injury
WO2017004560A1 (en) * 2015-07-02 2017-01-05 The Regents Of The University Of California Methods and compositions for amyloid aggregates
GB201603967D0 (en) 2016-03-08 2016-04-20 Univ Birmingham Biomarkers of traumatic brain injury
JP7029718B2 (ja) 2017-07-31 2022-03-04 国立研究開発法人量子科学技術研究開発機構 リン酸化タウタンパク質の測定方法
AU2020348382A1 (en) 2019-09-18 2022-04-28 Amydis, Inc. Methods of detecting neurological disorders via binding to phosphorylated tau protein
IL305647A (en) 2021-03-12 2023-11-01 Amydis Inc Methods for the detection of systemic amyloidosis by binding to misfolded protein or aggregates
JP2024525693A (ja) 2021-07-15 2024-07-12 アミディス， インコーポレイテッド 神経変性障害の診断のためにアミロイドおよびアミロイド様タンパク質を検出するためのフルオロフォアとしてのｎ－ヘテロシクリル置換２－シアノ－３－（ナフタレン－２－イル）アクリルアミド誘導体
WO2024155678A1 (en) 2023-01-18 2024-07-25 Amydis, Inc. Amyloid targeting agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143185A1 (en) * 2014-03-19 2015-09-24 Amydis Diagnostics Amyloid targeting agents and methods of using the same
WO2015188142A1 (en) * 2014-06-05 2015-12-10 Cedars-Sinai Medical Center Diagnosis and monitoring of traumatic brain injury by imaging retinal abnormalities
CN113271944A (zh) * 2018-11-02 2021-08-17 阿米达斯公司 用于对神经疾病进行检测的磷酸盐化合物

Also Published As

Publication number Publication date
US20210369873A1 (en) 2021-12-02
JP2025016675A (ja) 2025-02-04
EP3803416A4 (en) 2022-05-18
MA52796A (fr) 2021-04-14
JP2021525875A (ja) 2021-09-27
JP7381500B2 (ja) 2023-11-15
AU2019279001B2 (en) 2025-11-27
JP2024028695A (ja) 2024-03-05
CA3100700A1 (en) 2019-12-05
CN112424606A (zh) 2021-02-26
US12478693B2 (en) 2025-11-25
WO2019232422A1 (en) 2019-12-05
CN112424606B (zh) 2025-01-14
EP3803416A1 (en) 2021-04-14
JP7583895B2 (ja) 2024-11-14
CN119985995A (zh) 2025-05-13
AU2019279001A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
JP7583895B2 (ja) 外傷性脳損傷を検出するための組成物および方法
JP7664201B2 (ja) アミロイド標的剤及びその使用方法
JP2024177285A (ja) リン酸化タウタンパク質への結合を介した神経障害を検出する方法
CN113271944B (zh) 用于对神经疾病进行检测的磷酸盐化合物
BR112019020691A2 (pt) Composição farmacêutica contendo agonista do mor e agonista do kor, e usos da mesma
JP2013508384A (ja) アルファアドレナリン受容体モジュレーター
JP2007530591A (ja) 双極性障害を治療するための、ｎｋ３アンタゴニストの使用
WO2019005682A1 (en) USE OF BENZOTHIAZOLE AMPHIPHILES TO TREAT TRAUMATIC BRAIN INJURY
TW200307548A (en) Histamine-3 receptor ligands for diabetic conditions
TWI893772B (zh) 作為tyk2抑制劑的雜環化合物及合成與應用
US20260092037A1 (en) Crystalline salt forms of n-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl) methyl)-3-chloro-5-fluorobenzamide and methods of use thereof
JP2026508364A (ja) Ｔ型カルシウムチャネル調節因子の結晶塩、およびその使用方法
CN121991127A (zh) 用于对神经疾病进行检测的磷酸盐化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CI03 Correction of invention patent

Correction item: Description

Correct: Correct

False: Error

Number: 03-01

Page: ??

Volume: 41

CI03 Correction of invention patent